Inhibitory Effects of Amantadine on the Production of Pro-Inflammatory Cytokines by Stimulated in Vitro Human Blood

Kubera Marta,Maes Michael,Budziszewska Bogusława,Basta-Kaim Agnieszka,Leśkiewicz Monika,Grygier Beata,Rogóż Zofia,Lasoń Władysław
DOI: https://doi.org/10.1016/s1734-1140(09)70173-2
2009-01-01
Pharmacological Reports
Abstract:Treatment with amantadine (AMA), an N-methyl-D-aspartate (NMDA) receptor antagonist and antidepressant drug, increased the antidepressant activity of subsequent drugs in experimental studies and in patients suffering from treatment-resistant depression (TRD). Recent evidence indicates that depression may be accompanied by activation of an inflammatory response. These data indicate that pro-inflammatory cytokines may play a role in the etiology of depression, particularly in TRD. The present in vitro study shows the ability of AMA, used at concentrations between 10−7 to 10−5 M, to reduce the production of the pro-inflammatory cytokines, specifically interferon-ψ (IFN-ψ) and tumor necrosis factor-α (TNF-α). In addition, AMA treatment increased the production of the negative immunoregulator, interleukin-10 (IL-10). Furthermore, the combined treatment of AMA with fluoxetine (FLU), but not imi-pramine (IMF), had a stronger immunomodulatory effect on cytokine production than AMA alone. The above data provide additional rationale for the treatment of patients suffering from depression with a combination of AMA and a selective serotonin reuptake inhibitor.
What problem does this paper attempt to address?